EFR3A and cancer: Across all human cancers (n = 10,967 samples) there was a general bias towards EFR3A amplification, with ovarian, esophageal, breast, pancreatic, and liver cancers all exhibiting over 10% gene amplification (Supplementary Fig. 2a).